Drug Industry Continues to Bet Big on Artificial intelligence

Drug industry is looking to capitalize on artificial intelligence (AI) to streamline operating models and address R&D𠏋 productivity challenges.

Artificial intelligence (AI) may help pharma industries streamline operating models and address R&D productivity challenges, says GlobalData.

According to GlobalData's latest report, Digital Transformation and Emerging Technology in the Healthcare Industry's 2020, AI (58%) followed by big data (46%) are expected to be the most disruptive technologies in pharma in the coming two years.

India's Pharmaceutical Industry is Expected to Grow to $55 Billion by 2020
India's rapidly growing pharmaceutical market is expected to grow to $55 billion by 2020 and emerge as the sixth largest globally by size.

‘AI has a potential to revamp pharma industry ranging from target identification to marketing and commercialization activities.’
Read More..

Urte Jakimaviciute MSc, Senior Director of Market Research, comments: "The rising average cost to bring a drug to market, high attrition rate for pipeline products, and increase in average clinical cycle are among the main factors behind pharma's declining returns. No wonder digital transformation is seen as a positive step towards addressing R&D productivity challenges and developing more sustainable drug discovery processes."

Technological advancements are hoped to improve and streamline the drug development process.

Jakimaviciute continues: "Efficient and effective R&D is critical to the long-term success of any pharmaceutical business. The industry generates increasing amounts of data throughout all stages of value chain, and AI is seen as a valuable tool facilitating extraction of insights from those large datasets."

"By effectively utilizing information pharma companies could reduce drug discovery timeliness, accelerate clinical trials, cut down drug failure rates, and shorten drug approval thus making substantial costs savings."

"Pharma's faith in AI can be also associated with technology bringing some solid results. This year started with Sumitomo Dainippon Pharma and Exscientia's announcement that an AI-created compound will be used in human clinical trials for the first time. According to Exscientia, the exploratory research phase for DSP-1181 took less than 12 months to complete.

This is a fraction of the 4.5 years needed by conventional research techniques. The same year, Benevolent AI identified Eli Lilly's drug Baricitinib as a potential COVID-19 treatment, which is now in Phase III clinical trials.

"AI has a potential to revamp a spectrum of processes within pharma ranging from target identification to marketing and commercialization activities. Even though technologies like AI and big data are expected to disrupt the pharmaceutical sector, investments in these technologies will only pay off if the businesses can act on the results and insights they derive."

Source-Medindia